Structured evidence table for Chromium Fasting Glucose Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Fasting Glucose Meta-Analysis | 1 1 2 Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Meta-Analysis | 1 [] Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Meta-Analysis | 5 [] Metabolic syndrome increases the risk of cardiovascular diseases, kidney disease, eye problems, neuropathy, and diabetes-related complications such as foot ulcers and amputations. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Meta-Analysis | It includes central obesity, insulin resistance, hypertension, and dyslipidemia. | 1 | Babakr Abdullatif Taha (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes |
| Chromium Fasting Glucose Meta-Analysis | 1 1 Dysglycemia represents a heterogeneous clinical condition located along a pathophysiological continuum between normoglycemia and type 2 diabetes mellitus (T2DM) and is associated with a progressive and measurable increase in cardiometabolic risk, already evident in the early stages. | 4 | Cicero Arrigo Francesco Giuseppe (2026) | Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention |
| Chromium Fasting Glucose Meta-Analysis | Evidence derived from cohort studies and meta-analyses indicates that so-called prediabetes is not a metabolically neutral condition but rather an early disease stage characterized by increased all-cause and cardiovascular mortality []. | 4 | Cicero Arrigo Francesco Giuseppe (2026) | Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention |
| Chromium Fasting Glucose Meta-Analysis | A meta-analysis that included over 10 million individuals demonstrated that subjects with fasting plasma glucose levels between 100 and 125 mg/dL have a significantly increased risk of all-cause and cardiovascular mortality compared with normoglycemic individuals. | 4 | Cicero Arrigo Francesco Giuseppe (2026) | Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention |
Source documents